Qiu Jianxin, Terasaki Paul I, Waki Kayo, Cai Junchao, Gjertson David W
Terasaki Foundation Laboratory, Los Angeles, CA 90064, USA.
Transplantation. 2006 Jun 27;81(12):1658-61. doi: 10.1097/01.tp.0000226074.97314.e0.
Although patients positive for HIV were once thought to be unsuitable candidates for kidney transplantation, their increasing numbers with end-stage renal disease (ESRD) and the introduction of highly active antiretroviral therapy has indicated that they should no longer be excluded for transplantation. To counteract suggestions that human immunodeficiency virus (HIV) patients received suboptimal kidneys, we provide studies of kidneys transplanted from the same donor into patients with and without HIV.
United Network for Organ Sharing kidney transplant data between 1997 and 2004 were analyzed. Graft and patient survival of 38 HIV patients who had received a renal transplant were compared with the survival of 38 recipients who had received a graft from the same donor.
The 38 HIV-positive recipients were younger (49.0 vs. 52.3 years, P=0.14) and had lower peak panel-reactive antibodies (PRA; 5.1% vs. 15.6%, P=0.07) when compared with their bilateral donor to HIV-negative recipients. Sirolimus was used more frequently in HIV patients than in non-HIV patients (36.8% vs. 23.7%, P=0.09). The serum creatinine at 1, 3, and 5 years posttransplantation were higher in HIV patients when compared to non-HIV patients. Although not statistically significant, graft survival was higher among HIV-positive patients compared with their negative controls (76.1% vs. 65.1% at 5 years, P=0.21), as was patient survival (91.3% vs. 87.3% at 5 years, P=0.72). More grafts failed due to death with a functioning graft than rejection in HIV-positive patients.
This study supports the position that there is no longer an ethical question surrounding the use of kidneys for HIV-positive patients.
尽管曾经认为HIV阳性患者不适合进行肾移植,但随着终末期肾病(ESRD)患者数量的增加以及高效抗逆转录病毒疗法的引入,表明不应再将他们排除在移植之外。为了反驳关于人类免疫缺陷病毒(HIV)患者接受次优肾脏的观点,我们提供了将同一供体的肾脏移植给有HIV和无HIV患者的研究。
分析了1997年至2004年器官共享联合网络的肾移植数据。将38例接受肾移植的HIV患者的移植物和患者生存率与38例接受同一供体移植物的受者的生存率进行比较。
与HIV阴性受者的双侧供体相比,38例HIV阳性受者更年轻(49.0岁对52.3岁,P = 0.14),峰值群体反应性抗体(PRA)更低(5.1%对15.6%,P = 0.07)。HIV患者比非HIV患者更频繁地使用西罗莫司(36.8%对23.7%,P = 0.09)。与非HIV患者相比,HIV患者移植后1年、3年和5年的血清肌酐更高。尽管无统计学意义,但HIV阳性患者的移植物生存率高于其阴性对照(5年时为76.1%对65.1%,P = 0.21),患者生存率也是如此(5年时为91.3%对87.3%,P = 0.72)。在HIV阳性患者中,因移植肾功能正常时死亡导致的移植物失败比排斥反应更多。
本研究支持这样一种观点,即围绕HIV阳性患者使用肾脏不再存在伦理问题。